TRANSGENE (EPA:TNG) | WebDisclosure

Basculer en Français

9480	Companies
185558	Keywords
117947	Articles
99388	Press releases

Home
Companies
TRANSGENE

PRESS RELEASE

published on 03/27/2025 at 17:45, 8 months 9 days ago

Transgene franchit des étapes clés en 2024, avec la preuve de principe clinique de son vaccin individualisé contre le cancer ? Perspectives prometteuses pour 2025
Transgene publie ses résultats annuels 2024 et fait le point sur son activité, notamment la preuve de principe clinique de son vaccin individualisé contre le cancer. Perspectives prometteuses pour 2025

Résultats Annuels Perspectives Cancer Transgene Vaccin Thérapeutique
BRIEF

published on 01/21/2025 at 17:50, 10 months 15 days ago

Transgene se prépare pour le Biomed Forum des investisseurs

Investisseurs BIOMED Forum Immunothérapie Transgene Vecteurs Viraux
BRIEF

published on 01/21/2025 at 17:50, 10 months 15 days ago

Transgene Prepares for Biomed Investor Forum

Investors BIOMED Forum Immunotherapy Transgene Viral Vectors
PRESS RELEASE

published on 01/21/2025 at 17:45, 10 months 15 days ago

Transgene to Participate in the Biomed Forum Investor Conference
Transgene's management team to participate in the Biomed Forum Investor Conference in Paris on February 4, 2025

Investor Conference Paris BIOMED Forum Transgene February 4
PRESS RELEASE

published on 01/21/2025 at 17:45, 10 months 15 days ago

Transgene participera à la conférence investisseurs Biomed Forum
Transgene participera à la conférence investisseurs Biomed Forum le 4 février 2025. Présentation de ses immunothérapies contre le cancer reposant sur des vecteurs viraux

BIOMED Forum Immunothérapie Cancer Transgene Vecteurs Viraux
BRIEF

published on 11/05/2024 at 07:35, 1 year 1 month ago

Transgene and ProBioGen join forces for personalized cancer vaccines

Biotechnology Cancer Transgene ProBioGen Personalized Vaccines
BRIEF

published on 11/05/2024 at 07:35, 1 year 1 month ago

Transgene et ProBioGen unissent leurs forces pour les vaccins anti-cancer personnalisés

Biotechnologie Cancer Transgene ProBioGen Vaccins Personnalisés
PRESS RELEASE

published on 11/05/2024 at 07:30, 1 year 1 month ago

Transgene et ProBioGen collaborent pour faire progresser le développement des vaccins thérapeutiques individualisés
Transgene et ProBioGen collaborent pour développer les vaccins thérapeutiques individualisés, annoncent un accord de licence pour la lignée cellulaire AGE1.CR.pIX®

Transgene Vaccins ProBioGen Thérapeutiques Lignée Cellulaire
PRESS RELEASE

published on 10/14/2024 at 07:30, 1 year 1 month ago

Transgene fait le point sur l’étude de Phase II du vaccin thérapeutique TG4001 dans les cancers du col de l’utérus et anogénitaux HPV16 positifs, récurrents ou métastatiques
Transgene présente les résultats préliminaires de l'étude de Phase II du vaccin TG4001 dans les cancers du col de l'utérus HPV16 positifs, montrant une tendance positive malgré le non-atteinte de l'objectif principal

Transgene Vaccin Thérapeutique Étude De Phase II Cancer Du Col De L'utérus HPV16
PRESS RELEASE

published on 10/14/2024 at 07:30, 1 year 1 month ago

Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers

Accesswire

Published on 12/05/2025 at 21:45, 15 minutes ago

When the Architecture Becomes Visible: The SMX Revaluation Explained
Published on 12/05/2025 at 21:30, 30 minutes ago

The Identity Layer Beneath Everything: Why Markets Are Revaluing SMX All at Once
Published on 12/05/2025 at 21:20, 40 minutes ago

Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement
Published on 12/05/2025 at 21:00, 1 hour ago

The Repricing Event: Why Multiple Global Industries Are Suddenly Moving Toward SMX
Published on 12/05/2025 at 20:25, 1 hour 35 minutes ago

The Feedback Loop: Why SMX's Adoption in One Industry Accelerates Interest in All the Others

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 18:58, 3 hours 1 minute ago

EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:26, 3 hours 33 minutes ago

POS-Transaction in Own Shares
Published on 12/05/2025 at 18:15, 3 hours 44 minutes ago

Completion of merger to form Helvetia Baloise Holding Ltd
Published on 12/05/2025 at 17:51, 4 hours 8 minutes ago

Issue of Equity
Published on 12/05/2025 at 17:46, 4 hours 13 minutes ago

Booster Precision Components Holding GmbH announces the successful completion of its Written Procedure to amend and waive certain terms under the terms and conditions of the Bonds

Les Echos

Published on 12/05/2025 at 17:18, 4 hours 42 minutes ago

La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible
Published on 12/05/2025 at 17:18, 4 hours 42 minutes ago

The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 6 hours 49 minutes ago

Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 6 hours 49 minutes ago

Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 8 hours 1 minute ago

RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE

View all LES ECHOS COMFI WIRE